—
C+
C+ The full Closelook — membership. Open the C+ overview

Qiagen NV (QGEN) — chart, structure and Closelook read

Home› Indices›
Pick a ticker to load its detail page.

Company snapshot — Qiagen NV

QGEN in five paragraphs: what it makes and sells, where it sits in the Closelook stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Qiagen supplies the kits, reagents and instruments that turn a biological sample into a readable molecular result. Its consumables extract and purify DNA and RNA, prepare samples for PCR and next-generation sequencing, and support tests used in oncology, infectious disease and prenatal screening. It also sells the PCR and sequencing-prep instruments that run alongside these consumables, plus software that helps interpret the resulting data. The company is based in Venlo in the Netherlands and serves laboratories, hospitals and research groups worldwide.
Where it sits in the stack
Qiagen has no seat in our Rubin build-out index; it sits instead in the diagnostics and life-science tools sleeve of our wider healthcare universe, supplying the sample-preparation consumables that molecular labs consume repeatedly rather than a one-off tool purchase.
Who it is priced against
Closelook has not assigned Qiagen a peer group; the market usually places it alongside Thermo Fisher Scientific and Roche Diagnostics as suppliers of molecular-testing consumables and instruments.
Why Closelook tracks it
Qiagen sits in the Russell 1000 but carries no seat in Rubin or our Halo research index, and the diary has not yet quoted it or scored it, so its Closelook score is still being built.
What the diary watches
The diary watches whether Qiagen's recovery from its recent lower price levels continues or fades back toward those lows.

Qiagen NV (QGEN) trades on US exchanges.

Written from the company’s public profile and Closelook’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

Signals for this name

Every Closelook reading that exists for QGEN, from the same nightly bakes the boards use. Research diary readings, not advice.

Who it is priced against Diagnostics & Research · United States · 8 names with week and year-to-date

Peer group

Diagnostics & Research · United States

This name carries no Closelook score, so its cohort ranks on trend state — distance to the 50- and 200-day averages — never on a score it does not have.

Compared against QGEN on the nightly bakes; the Peers tab ranks the cohort on the Closelook scores where it exists.

Dividends and capital return trailing yield 5.26%, semi-annual · last 2.29 USD on 2026-07-07

Dividends and capital return

What QGEN pays out and buys back — distributions read from the price series, money terms from the filings.

  • Trailing 12 months 2.34 USD per share · a 5.26% yield on the 2026-09-17 close 2 distributions, paid twice a year 2026-09-17
  • Change on the year +582.3% against the prior twelve months prior twelve months 0.34 USD per share
  • Last distribution 2.29 USD per share as the price series records it, within days of the ex-date 2026-07-07
  • By calendar year 2025: 0.34 USD · 2026: 2.34 USD to date first distribution recorded in the three-year window: 2025-01-29

Per-share amounts are derived from the adjusted price series in the listing currency, so dates sit within days of the ex-date; filing figures come from the fundamentals feed for the last reported fiscal year. An investment diary, not a recommendation.

Weather around the name 3 macro readings: Money Temperature, Factor regime, Sovereign pressure

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 55/100 · S&P 500 fund at 58, above its 50- and 200-day averagesEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-09-17
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 94th percentile of the window, +2.7% over 20 sessions. Factor regime → 2026-09-17
  • Sovereign pressure Index 0.00 · down 0.41 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-09-17

FAQ · from the current data · as of 2026-09-18

Quick answers

What is Qiagen NV (QGEN)?

Qiagen NV trades as QGEN on the US exchange (United States) in the Closelook research universe, as of the registry build of 2026-09-18.

Is QGEN in a Closelook index?

Not currently — Qiagen NV is tracked in the Closelook research universe but is not a constituent of a Closelook functional index as of 2026-09-18.

Where does QGEN trade against its moving averages?

Uptrend stack intact: Trades +4.5% vs the 50-day and +5.1% vs the 200-day average, 23.2% below the 52-week high and +36.4% off the 52-week low; a golden cross printed 3 sessions ago. Computed from daily closes. As of 2026-09-17 — a technical state from the nightly Closelook bake, not advice. The Technical tab carries the full row.

What does Qiagen NV do?

Qiagen supplies the kits, reagents and instruments that turn a biological sample into a readable molecular result. Its consumables extract and purify DNA and RNA, prepare samples for PCR and next-generation sequencing, and support tests used in oncology, infectious disease and prenatal screening. It also sells the PCR and sequencing-prep instruments that run alongside these consumables, plus software that helps interpret the resulting data. Closelook has not assigned Qiagen a peer group; the market usually places it alongside Thermo Fisher Scientific and Roche Diagnostics as suppliers of molecular-testing consumables and instruments.

Where does Qiagen NV sit in the AI build-out?

Qiagen has no seat in our Rubin build-out index; it sits instead in the diagnostics and life-science tools sleeve of our wider healthcare universe, supplying the sample-preparation consumables that molecular labs consume repeatedly rather than a one-off tool purchase. Qiagen sits in the Russell 1000 but carries no seat in Rubin or our Halo research index, and the diary has not yet quoted it or scored it, so its Closelook score is still being built.

Does Qiagen NV pay a dividend?

Qiagen NV has paid 2.34 USD per share over the last twelve months, paid twice a year, a trailing yield of 5.26% on the 2026-09-17 close; the last distribution recorded in the price series was 2.29 USD on 2026-07-07. The "Dividends and capital return" block on this page carries the lines.

What does this page show?

A live price chart with SMA overlays and drawing tools for QGEN, performance metrics, index-membership context and the Closelook structure read — an investment research diary view, not investment advice.

Related in the Closelook universe

then Diagnostics & Research. Scored names rank on their Closelook score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.